News | August 02, 2025
Sun Pharmaceutical Q1 FY26 consolidated PAT falls by 20% to Rs. 2,278 Cr
India Formulation sales accounted for 34.2% of total consolidated sales for the quarter
India Formulation sales accounted for 34.2% of total consolidated sales for the quarter
Ajanta Pharma has reported total income of Rs. 1,328.98 crores during the period ended June 30, 2025
The company would be commissioning 3 hubs in Q2 FY26 across our Core Geography and West Bengal
Torrent Pharmaceuticals has reported total income of Rs. 3,141 crores during the period ended June 30, 2025
Piramal Pharma has reported total income of Rs. 1,992.11 crores during the period ended June 30, 2025
Sigachi Industries has reported total income of Rs. 132.18 crores during the period ended June 30, 2025
Laurus Labs has reported total income of Rs. 1,580 crores during the period ended June 30, 2025
Solara Active Pharma Sciences has reported total income of Rs. 320.13 crores during the period ended June 30, 2025
_256_384.jpg)
Cipla has reported total income of Rs. 7,216.03 crores during the period ended June 30, 2025
Anti-cancer patent now validated in Spain, the UK, and as a Unitary Patent covering multiple EU member states
Subscribe To Our Newsletter & Stay Updated
